论文部分内容阅读
在过去的十余年里,多种基因组学和组织学技术加快了新的乳腺癌诊疗模式的发展,对患者进行分子水平诊断和个性化治疗成为今后的发展趋势。与基因组学和组织学技术快速发展相比较,用于指导乳腺癌的筛查和治疗的肿瘤标志物研究进展却微乎其微,尤其是对血清或组织中乳腺癌特异性标志物的检测。该文就基因组学与蛋白质学在乳腺癌分子诊断学应用进展中存在巨大差距的潜在原因,以及改进蛋白质组学研究设计的策略予以综述。
In the past ten years, a variety of genomics and histology technologies have accelerated the development of new breast cancer diagnosis and treatment models, and molecular diagnosis and personalized treatment of patients have become the trend of the future. There has been little progress in the development of tumor markers to guide the screening and treatment of breast cancer compared to rapid advances in genomics and histology, especially in the detection of breast cancer-specific markers in serum or tissue. This article reviews the potential causes of the huge gap between genomics and proteomics in the application of molecular diagnostics in breast cancer and the strategies for improving proteomics research design.